DDIT3 and diffuse large B-cell lymphoma: About 62% of patients enrolled in the trial had stage IV disease and had a 2-year PFS of 72.6% in the Pola-R-CHP arm vs. 66.1% in the R-CHOP arm with a hazard ratio (HR) of 0.8, however, the 95% CI ranged from 0.6-1.1, which falls out of range of statistical significance, but suggests that patients with advanced staged DLBCL benefit more from pola-R-CHP as compared to R- CHOP.